Global UAV Announces Proposed Acquisition of Nexus Peptide Sciences Inc.

Global UAV Technologies Ltd. (CSE: UAV) (OTC Pink: YRLLF) (FSE: 1OZ) (the " Company ") is pleased to announce that it is has entered into a letter of intent (the " LOI ") dated July 27, 2026 with Nexus Peptide Sciences Inc. (" Nexus "), a private corporation existing under the laws of British Columbia, pursuant to which the Company would acquire (the " Transaction ") all of the outstanding securities of Nexus from the securityholders of Nexus (collectively, the " Nexus Shareholders ").

Nexus Peptide Sciences Inc. is a private biotechnology company, based in Vancouver, British Columbia. Nexus is developing optimized peptide formulations and next-generation delivery systems intended to improve stability, absorption and practical use across metabolic health, recovery and longevity applications. Peptides are short chains of amino acids that act as native signalling molecules, regulating metabolism, repair, immunity and cognition. Nexus' platform is directed at what the company identifies as the principal constraint on peptide adoption — the molecule itself and the route of delivery, as most peptides degrade rapidly, struggle to cross biological barriers and require injection to remain stable. Nexus' work spans five areas: molecular optimization (sequence and structural refinement to improve stability, half-life and target selectivity); formulation chemistry (excipient and carrier systems engineered for solubility, shelf-stability and consistent dosing); researching optimal delivery systems (needle-free formats including transdermal patches, oral platforms and absorption-enhanced carriers); quality and verification (manufacturing in approved facilities with batch-level third-party analytical testing for identity, purity and contamination); and regulatory alignment (monitoring of U.S. and international policy to align product positioning with the evolving framework for peptide-based products).

The LOI is a non-binding agreement which sets out the principal terms on which the parties have agreed to complete the Transaction. Subject to satisfactory due diligence and successful additional negotiations, the parties intend to enter into a definitive agreement with respect to the Transaction (the " Definitive Agreement ") on or before August 31, 2026. The Transaction is considered a Fundamental Change pursuant to the policies of the Canadian Securities Exchange (the " CSE "), requiring the CSE to review and approve the Transaction. The Transaction is an arm's length transaction.

On completion of the Transaction (the " Closing "), the Company has agreed to issue an aggregate of 20,300,000 common shares (each, a " Share ") in the capital of the Company and 7,000,000 transferable share purchase warrants (each, a " Warrant ") of the Company to the Nexus Shareholders on a pro-rata basis. Each Warrant is exercisable into one additional Share (each, a " Warrant Share ") at an exercise price of $0.10 per Warrant Share for a period of two years following the Closing in consideration for the acquisition of all of the securities of Nexus. Immediately before the Closing, Global UAV has agreed that there will be no more than 33,000,000 Shares and 17,000,000 share purchase warrants issued and outstanding, with such warrants to have an exercise price of $0.10 per Share. At the time of Closing, Nexus will become a wholly-owned subsidiary of the Company. If issued, the Shares and Warrants may be subject to certain restrictions on transfer pursuant to the requirements of applicable law.